| |
Choosing the right partner to deliver decentralised clinical trials is crucial. ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities. .png)
|
|
Today’s Big NewsSep 22, 2023 |
|
Avoid costly manufacturing delays by establishing the identity, purity and quality of your starting materials. Download this comprehensive guide to raw materials testing. Learn more. .png)
|
|
| By Nick Paul Taylor AstraZeneca and Daiichi Sankyo are coming for Gilead Sciences' breast cancer business. The partners plan to file for approval of datopotamab deruxtecan (Dato-DXd) after linking their antibody-drug conjugate to improved outcomes, although the immature overall survival data leave a key question unanswered. |
|
|
|
| Philadelphia, PA |  |
|
|
By Annalee Armstrong Viral disease biotech Antios Therapeutics shut down earlier this year after an FDA hold on its lead hepatitis B therapy due to a serious adverse event proved insurmountable. |
By Nick Paul Taylor Abpro is taking a second run at the public markets. Five years after pulling out of a planned IPO, the antibody specialist is back with a SPAC. |
Sponsored by Rise to Health Coalition Two leaders supporting the Rise to Health Coalition discuss the need for coordinated and collective action across sectors to advance health equity |
|
With the acquisition of XenoTech, BioIVT’s labs have further expanded, allowing for quicker turnaround and more options tailored to your research objectives. View Service Options >> 
|
|
By Gabrielle Masson After an FDA rejection earlier this year, ImmunityBio has laid off around 50 employees across California and Florida, its second layoff wave in less than a year. |
By Gabrielle Masson,Max Bayer GSK’s Senior Vice President and Head of Research John Lepore, M.D., has left the Big Pharma. The R&D leader exits after nearly 15 years with GSK and more than five in his most recent position. |
By Fraiser Kansteiner Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Following a series of trial shortfalls this year in melanoma, colorectal cancer and head and neck squamous cell carcinoma, the duo has missed the mark in yet another set of clinical trials—this time in non-small cell lung cancer. |
By Conor Hale According to the manufacturer, degrading capacitors could leak material and fry parts of the circuit board, potentially leading to interruptions in ventilation. |
By Eric Sagonowsky After AstraZeneca's Farxiga won a class-first chronic kidney disease approval back in 2021, Eli Lilly and Boehringer are entering the fray with their SGLT2 drug Jardiance. |
By Noah Tong CHICAGO—Walgreens execs gave reporters a peek behind the curtain at its Chicago primary care office and micro-fulfillment center. Here's what we learned. |
By Angus Liu BeiGene and Novartis have parted ways on the PD-1 drug tislelizumab. Roche's Genentech signed a radiopharmaceutical peptide conjugate deal with Japan's PeptiDream. Biocon named a new group CEO. And more. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we take a closer look at how one of New York's largest health systems integrated behavioral health services at several of its OB practices, and the impact that change has had. |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Brought to you by the editors behind Fierce Biotech, this conference is a unique venue where biotech executives can network and learn how to improve their partnership and pipeline strategies. It’s the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials. Countdown is on! Register today to save $200 
|
|
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
